Abstract
The effects of exchange transfusion with Fluosol DA (FDA) or stroma-free hemoglobin on the outcome of pneumococcal infection in rats were determined. Rats were sham transfused or exchange transfused with 25 ml of FDA or stroma-free hemoglobin. They were then challenged intraperitoneally with Streptococcus pneumoniae type 3 and treated with penicillin for 120 h. Only 2 of 15 (13.3%) FDA-transfused rats were alive at 312 h compared with 11 of 15 (73.3%) concurrently studied sham-transfused control rats (P = 0.0016). Of 10 stroma-free hemoglobin-transfused rats and 10 concurrently studied sham-transfused control rats (P = 0.98), 8 from each group (80%) were alive at 312 h. Penicillin therapy only suppressed pneumococcal infection in FDA-transfused rats, and relapse occurred after therapy was stopped. This effect could not be attributed to interference with the bactericidal activity of penicillin against pneumococci, to an alteration in the pneumococcal burden before penicillin therapy or to an alteration of the leukocyte and polymorphonuclear leukocyte response by FDA. In contrast, pneumococcal infection in stroma-free hemoglobin-transfused rats was cured with penicillin therapy. These data showed that FDA altered the ability of rats to respond to pneumococcal infection.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- DeVenuto F., Friedman H. I., Neville J. R., Peck C. C. Appraisal of hemoglobin solution as a blood substitute. Surg Gynecol Obstet. 1979 Sep;149(3):417–436. [PubMed] [Google Scholar]
- Geyer R. P. PFC as blood substitutes--an overview. Prog Clin Biol Res. 1983;122:157–168. [PubMed] [Google Scholar]
- Geyer R. P. Potential uses of artificial blood substitutes. Fed Proc. 1975 May;34(6):1525–1528. [PubMed] [Google Scholar]
- Hodges G. R., Worley S. E., Degener C. E., Clark G. M. Antigenicity and protective effects of type 3 pneumococcal polysaccharide in rats. Infect Immun. 1980 Jun;28(3):832–836. doi: 10.1128/iai.28.3.832-836.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kemner J. M., Snodgrass W. R., Worley S. E., Hodges G. R., Clark G. M., Hignite C. E. Interaction of oxygen-carrying resuscitation fluids with morphine. J Lab Clin Med. 1984 Sep;104(3):433–444. [PubMed] [Google Scholar]
- Lutz J. Studies on RES function in rats and mice after different doses of fluosol. Prog Clin Biol Res. 1983;122:197–208. [PubMed] [Google Scholar]
- Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966 Mar;50(3):163–170. [PubMed] [Google Scholar]
- Riess J. G., Le Blanc M. Perfluoro compounds as blood substitutes. Angew Chem Int Ed Engl. 1978 Sep;17(9):621–634. doi: 10.1002/anie.197806213. [DOI] [PubMed] [Google Scholar]
- Vercellotti G. M., Hammerschmidt D. E., Craddock P. R., Jacob H. S. Activation of plasma complement by perfluorocarbon artificial blood: probable mechanism of adverse pulmonary reactions in treated patients and rationale for corticosteroids prophylaxis. Blood. 1982 Jun;59(6):1299–1304. [PubMed] [Google Scholar]
- Virmani R., Warren D., Rees R., Fink L. M., English D. Effects of perfluorochemical on phagocytic function of leukocytes. Transfusion. 1983 Nov-Dec;23(6):512–515. doi: 10.1046/j.1537-2995.1983.23684074274.x. [DOI] [PubMed] [Google Scholar]